Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 12/20 | 0.48 |
| ▸ | F3 | P13726 | 7/20 | 0.48 |
| ▸ | F7 | P08709 | 6/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23474448 | 0.94 | F2 (0.48) | F2F3F7NTRK1NTRK3 | |
| SCHEMBL30765597 | 0.93 | F2 (0.51) | F2F3F7NTRK1NTRK3 | |
| SCHEMBL23474319 | 0.93 | F2 (0.53) | F2F3F7NTRK1NTRK3 | |
| SCHEMBL23474223 | 0.91 | F2 (0.49) | F2F3F7NTRK1NTRK3 | |
| SCHEMBL23460598 | 0.91 | F2 (0.49) | F2F3F7NTRK1NTRK3 | |
| SCHEMBL23474444 | 0.90 | F2 (0.49) | F2F3F7 | |
| Trifluoroacetic Acid SCHEMBL23460813 | 0.89 | F2 (0.49) | F2F3F7NTRK1NTRK3 | |
| SCHEMBL23474404 | 0.88 | F2 (0.46) | F2F3F7NTRK1NTRK3 | |
| SCHEMBL23474396 | 0.88 | F3 (0.47) | F2F3F7NTRK1NTRK3 | |
| SCHEMBL23474433 | 0.87 | F2 (0.56) | F2F3F7PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |